VKTX vs. LEGN, CERE, ELAN, ASND, JAZZ, ITCI, ROIV, BPMC, CYTK, and CTLT
Should you be buying Viking Therapeutics stock or one of its competitors? The main competitors of Viking Therapeutics include Legend Biotech (LEGN), Cerevel Therapeutics (CERE), Elanco Animal Health (ELAN), Ascendis Pharma A/S (ASND), Jazz Pharmaceuticals (JAZZ), Intra-Cellular Therapies (ITCI), Roivant Sciences (ROIV), Blueprint Medicines (BPMC), Cytokinetics (CYTK), and Catalent (CTLT). These companies are all part of the "pharmaceutical preparations" industry.
Legend Biotech (NASDAQ:LEGN) and Viking Therapeutics (NASDAQ:VKTX) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership, community ranking and earnings.
In the previous week, Legend Biotech had 11 more articles in the media than Viking Therapeutics. MarketBeat recorded 28 mentions for Legend Biotech and 17 mentions for Viking Therapeutics. Legend Biotech's average media sentiment score of 0.79 beat Viking Therapeutics' score of 0.55 indicating that Viking Therapeutics is being referred to more favorably in the news media.
Viking Therapeutics has a net margin of 0.00% compared to Viking Therapeutics' net margin of -135.92%. Legend Biotech's return on equity of -18.41% beat Viking Therapeutics' return on equity.
Viking Therapeutics received 540 more outperform votes than Legend Biotech when rated by MarketBeat users. Likewise, 79.97% of users gave Viking Therapeutics an outperform vote while only 64.13% of users gave Legend Biotech an outperform vote.
Legend Biotech has a beta of 0.12, suggesting that its stock price is 88% less volatile than the S&P 500. Comparatively, Viking Therapeutics has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500.
70.9% of Legend Biotech shares are held by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are held by institutional investors. 0.0% of Legend Biotech shares are held by insiders. Comparatively, 4.7% of Viking Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Viking Therapeutics has lower revenue, but higher earnings than Legend Biotech. Viking Therapeutics is trading at a lower price-to-earnings ratio than Legend Biotech, indicating that it is currently the more affordable of the two stocks.
Legend Biotech presently has a consensus target price of $82.74, suggesting a potential upside of 83.21%. Viking Therapeutics has a consensus target price of $112.38, suggesting a potential upside of 67.72%. Given Viking Therapeutics' higher probable upside, equities analysts plainly believe Legend Biotech is more favorable than Viking Therapeutics.
Summary
Viking Therapeutics beats Legend Biotech on 13 of the 18 factors compared between the two stocks.
Get Viking Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Viking Therapeutics Competitors List
Related Companies and Tools
